Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

T2255

Sigma-Aldrich

Trifluorothymidine

≥99% (HPLC)

Synonyme(s) :

α,α,α-Trifluorothymidine, 2′-Deoxy-5-trifluoromethyluridine, Trifluorothymine deoxyriboside, Trifluridine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H11F3N2O5
Numéro CAS:
70-00-8
Poids moléculaire :
296.20
Numéro CE :
200-722-8
Numéro MDL:
MFCD00006534
Code UNSPSC :
41106305
ID de substance PubChem :
24900027
Nomenclature NACRES :
NA.51

Source biologique

synthetic

Pureté

≥99% (HPLC)

Forme

powder

Pf

190-193 °C (lit.)

Solubilité

water: 50 mg/mL, clear, colorless

Température de stockage

−20°C

Chaîne SMILES 

OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(C(=O)NC2=O)C(F)(F)F

InChI

1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1

Clé InChI

VSQQQLOSPVPRAZ-RRKCRQDMSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Trifluorothymidine has been used as a component of selection medium to screen thymidine kinase (TK) mutants in lymphoma cells, human lymphoblastoid TK6 cells, and L5178Y mouse lymphoma cells.

Actions biochimiques/physiologiques

Trifluorothymidine is a thymidine analog and is light sensitive. TFT serves as a thymidine kinase substrate to study enzyme specificity and kinetics. Incorporation of phosphorylated TFT into DNA induces damage, making it useful for DNA repair studies. TFT may also be used in the inhibition of thymidylate synthase and in screening mutant thymidine kinase gene.. It elicits antitumor activity in gastrointestinal (GI) cancers and has therapeutic potential to treat herpetic keratitis.

Conditionnement

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H341,H351,H361d

Classification des risques

Carc. 2 - Muta. 2 - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Novel cell death mechanisms of trifluorothymidine.
Bijnsdorp IV, Kruyt F, et al.
Nucleic Acids Symposium Series, 52, 649-649 (2008)
I V Bijnsdorp et al.
Nucleosides, nucleotides & nucleic acids, 27(6), 699-703 (2008-07-05)
Trifluorothymidine (TFT), a potent anticancer agent, inhibits thymidylate synthase (TS) and is incorporated into the DNA, both events resulting in cell death. Cell death induction related to DNA damage often involves activation of p53. We determined the role of p53
Connie Kang et al.
Drugs, 79(14), 1583-1590 (2019-09-07)
Trifluridine/tipiracil (Lonsurf®) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. Trifluridine/tipiracil has recently been granted an additional indication in the USA for the treatment of metastatic gastric cancer, including gastroesophageal junction
Marc Peeters et al.
Future oncology (London, England), 14(16), 1629-1645 (2018-04-28)
Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article
Olaf H Temmink et al.
Molecular cancer therapeutics, 9(4), 1047-1057 (2010-04-08)
Trifluorothymidine (TFT) is part of the novel oral formulation TAS-102, which is currently evaluated in phase II studies. Drug resistance is an important limitation of cancer therapy. The aim of the present study was to induce resistance to TFT in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique